The detection of PTN expression in primary breast cancers and in estrogen receptor negative breast cancer cell lines and its pro-angiogenic and pro-metastatic function [19], [22], [34], [35] make PTN a good candidate for therapeutic targeting. This evidence concerns the gene ESR1 and breast carcinoma.